Olmesartan medoxomil

Drug Profile

Olmesartan medoxomil

Alternative Names: Alteis; Benetor; Benevas; Benicar; Cardosal; CS 866; CS 866RN; CS-866DM; Ixia; Mencord; Olmec; Olmes; Olmesartan; Olmetec; Olmighty; Olvance™; Omesar; Openvas; Tensonit; Votum

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Daiichi Sankyo Company
  • Developer Allergan; Daewoong Pharmaceutical; Daiichi Sankyo Company; Menarini; Merck & Co; Pfizer; Sun Pharmaceutical Industries
  • Class Antihypertensives; Eye disorder therapies; Imidazoles; Small molecules; Tetrazoles
  • Mechanism of Action Angiotensin type 1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Hypertension
  • Discontinued Diabetic nephropathies

Most Recent Events

  • 15 Dec 2016 Biomarkers information updated
  • 26 Oct 2016 First generic equivalent launched in USA for Hypertension (PO)
  • 01 Jan 2016 Daiichi-Sankyo initiates a clinical trial for Hypertension (In the elderly) in Japan (PO) (UMIN000020471)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top